RAPT Therapeutics (RAPT) Cash & Equivalents: 2020-2024
Historic Cash & Equivalents for Therapeutics (RAPT) over the last 5 years, with Sep 2024 value amounting to $37.9 million.
- Therapeutics' Cash & Equivalents fell 29.99% to $37.9 million in Q3 2024 from the same period last year, while for Sep 2024 it was $37.9 million, marking a year-over-year decrease of 29.99%. This contributed to the annual value of $47.5 million for FY2023, which is 21.91% up from last year.
- Latest data reveals that Therapeutics reported Cash & Equivalents of $37.9 million as of Q3 2024, which was up 2.22% from $37.1 million recorded in Q2 2024.
- Therapeutics' 5-year Cash & Equivalents high stood at $91.5 million for Q1 2020, and its period low was $20.2 million during Q3 2020.
- Moreover, its 3-year median value for Cash & Equivalents was $45.3 million (2024), whereas its average is $43.1 million.
- The largest annual percentage gain for Therapeutics' Cash & Equivalents in the last 5 years was 197.75% (2021), contrasted with its biggest fall of 72.99% (2021).
- Quarterly analysis of 5 years shows Therapeutics' Cash & Equivalents stood at $24.9 million in 2020, then decreased by 3.58% to $24.0 million in 2021, then soared by 62.09% to $38.9 million in 2022, then increased by 21.91% to $47.5 million in 2023, then decreased by 29.99% to $37.9 million in 2024.
- Its last three reported values are $37.9 million in Q3 2024, $37.1 million for Q2 2024, and $45.3 million during Q1 2024.